A Phase 3 interventional study of garetosmab in Fibrodyplasia Ossificans Progressiva (FOP) and Heterotopic Ossification (HO), sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-11-01.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP.
The primary efficacy objective of the study is to assess the effect of garetosmab on Heterotopic ossification (HO) in Japanese adult patients with FOP, as determined by the number of new heterotopic bone lesions identified by computed tomography (CT).
38 studies on the registry are indexed under Ossification, Heterotopic; 7 are open to participants now.
Browse Ossification, Heterotopic studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: garetosmab
Repeated doses administered intravenously (IV) every four weeks (Q4W)
Also known as: REGN2477
Incidence and severity of treatment-emergent adverse event (TEAEs)
Time frame: Through week 28
Number of new HO lesions as assessed by CT
Time frame: At week 28
Total volume of new HO lesions as assessed by CT
Time frame: At week 28
Number of new HO lesions as assessed by positron emission tomography (PET)
Time frame: At week 28
Total lesion activity in new HO lesions as assessed by PET
Time frame: At week 28
Percent of patients with new HO lesions as assessed by CT
Time frame: At week 28
Percent of patients with new HO lesions as assessed by PET
Time frame: At week 28
Percent of patients with investigator-assessed flare-ups
Time frame: Baseline to week 28
Percent of patients with investigator-assessed flare-ups
Time frame: Baseline to week 56
Percent of patients with flare-ups assessed by patient e-diary
Time frame: Baseline to week 28
Percent of patients with flare-ups assessed by patient e-diary
Time frame: Baseline to week 56
Number of new HO lesions as assessed by CT
Time frame: At week 56
Total volume of new HO lesions as assessed by CT
Time frame: At week 56
Percent of patients with new HO lesions as assessed by CT
Time frame: At week 56
Number of new HO lesions as assessed by PET
Time frame: At week 56
Total lesion activity in new HO lesions as assessed by PET
Time frame: At week 56
Percent of patients with new HO lesions as assessed by PET
Time frame: At week 56
Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET
Time frame: Baseline and week 28
Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET
Time frame: Baseline and week 56
Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET
Time frame: Baseline and week 28
Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET
Time frame: Baseline and week 56
Change in total lesion activity by PET
Time frame: Baseline and week 28
Change in total lesion activity by PET
Time frame: Baseline and week 56
Percent change in total lesion activity by PET
Time frame: Baseline and week 28
Percent change in total lesion activity by PET
Time frame: Baseline and week 56
Change in the total volume of HO lesions as assessed by CT
Time frame: Baseline and week 28
Change in the total volume of HO lesions as assessed by CT
Time frame: Baseline and week 56
Percent change in the total volume of HO lesions as assessed by CT
Time frame: Baseline and week 28
Percent change in the total volume of HO lesions as assessed by CT
Time frame: Baseline and week 56
Change in number of HO lesions as assessed by PET
HO lesions defined as target and new lesions relative to baseline.
Time frame: Baseline and week 28
Change in number of HO lesions as assessed by PET
Defined above
Time frame: Baseline and week 56
Change in the number of HO lesions detectable by CT
Defined above
Time frame: Baseline and week 28
Change in the number of HO lesions detectable by CT
Defined above
Time frame: Baseline and week 56
Time-weighted average (standardized area under curve [AUC]) change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS)
The NRS is a categorical rating scale used by patients to rate their pain associated with FOP. Patients will be asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain).
Time frame: Baseline through week 28
Time-weighted average (standardized AUC) change in daily pain due to FOP, as measured using the daily NRS
Time frame: Baseline through week 56
Total dosage of glucocorticoids use
Time frame: Through week 56
Incidence and severity of TEAEs
Time frame: Through week 56
Concentration of total activin A in serum over time
Time frame: Through week 56
Pharmacokinetic (Pk) Profile - concentrations of garetosmab in serum over time
Time frame: Through week 56
Immunogenicity as measured by Anti-drug antibodies (ADA) to garetosmab over time
Time frame: Through week 28
Percent change from baseline in biomarkers of bone formation levels in serum
Time frame: Through week 28
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Oct 2021; primary completion for Mar 2022, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garetosmab